Patient with newly diagnosed type 2 diabetes? Remember these steps

Nearly 40 antihyperglycemic agents have been approved existing antihyperglycemic medications are constantly gaining FDA approval for new indications for common type 2 diabetes mic benefits, the sodium-glucose cotransporter-2 (SGLT2) inhibitors have been approved for use in patients with T2D and established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk for major adverse cardiovascular events (MACE; canagliflozin), risk for hospitalization for heart failure (dapaThe plethora of new agents and new data for existing agents, coupled with the annual release of guidelines from the American Diabetes Association (ADA) and practice recommendations from several other professional organizations,5-7 make it challenging for family physicians to stay current and provide the most up-to-date, evidence-based care. In this article, we provide advice on how to approach the screening, diagnosis, and evaluation of T2D, and on how to manage newly diagnosed T2D.

Automated summary

Nearly 40 antihyperglycemic agents have been approved, and existing antihyperglycemic medications are gaining FDA approval for new indications for common type 2 diabetes and related cardiovascular diseases. The sodium-glucose cotransporter-2 (SGLT2) inhibitors have been approved for use in patients with T2D and established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk for major adverse cardiovascular events (MACE) and hospitalization for heart failure.